Division of ConforMIS Inc.
Latest From Conformis Inc.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.
Although certainly not a given, many researchers and companies are pursing the eventual goal of bioprinting human organs, starting with the three-dimensional printing of a structure that has cellular function. If organ function via bioprinting becomes a reality for the skin, bone, lung, liver, eye and/or kidney, among other potential organs, the market opportunity could be in the billions. But challenges, including cost and ethics, stand in the way of this milestone in regenerative medicine.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- ConforMIS Inc.
- North America
- Parent & Subsidiaries
- ConforMIS Inc.
- Senior Management
- Mark Augusti, MD, Pres. & CEO
- Contact Info
Phone: (781) 345-9001
600 Technology Park Dr.
Billerica, MA 01821
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.